Australasian Journal of Dermatology最新文献

{"title":"Perspectives on oral benzodiazepine use for anxiety in Mohs micrographic surgery: A response to the Australian survey","authors":"Ching Ching Hsieh BSc,&nbsp;Lien-Chung Wei MD, MPH","doi":"10.1111/ajd.14378","DOIUrl":"10.1111/ajd.14378","url":null,"abstract":"<p>This letter responds to the recent Australian survey by Harris and Lee (<i>Australas J Dermatol</i>, 2024, doi: 10.1111/ajd.14361) on the use of oral benzodiazepines for anxiety management in Mohs micrographic surgery (MMS). While commending the authors' efforts, we provide additional perspectives on current practices, recent evidence and safety considerations. We highlight the alignment with U.S. practices, discuss a recent randomized controlled trial supporting diazepam's efficacy and emphasize the importance of non-pharmacological interventions. The letter also addresses the need for flumazenil availability and calls for standardized guidelines and further research to optimize patient care in MMS.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"663-664"},"PeriodicalIF":2.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data on the efficacy and safety of hedgehog pathway inhibitors in patients with basal cell carcinoma: Experience of a tertiary Australian centre","authors":"K. Truong BPharm, MD, MMed,&nbsp;M. Peera MBBS,&nbsp;R. Liu BMed MD, MPH, FACD,&nbsp;M. Wijaya BMed MD, MPhil,&nbsp;M. Jones-Caballero MD, PhD, FACD,&nbsp;R. Ruiz Araujo MD, FACD,&nbsp;P. Fernandez-Penas MD, PhD, FACD","doi":"10.1111/ajd.14373","DOIUrl":"10.1111/ajd.14373","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Basal cell carcinomas (BCCs) are the most common cancers worldwide. Although most BCCs are amenable to local treatment, there are limited therapeutic options for surgically unresectable locally advanced and metastatic BCCs. Activation of the sonic hedgehog signalling pathway plays a significant role in the development of most BCCs. Hedgehog pathway inhibitors (HPIs) can be used to inhibit this pathway. Efficacy and safety data on HPI use in Australia is scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to present the effectiveness and safety of HPI at a tertiary dermatology referral centre.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective analysis of the clinical charts of all patients with BCC treated with an HPI at a tertiary Dermatology referral centre in New South Wales, Australia from 1 January 2016 to 1 July 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-three patients with BCCs were treated with an HPI; 11 locally advanced, 8 multiple, 3 basal cell naevus syndrome and 1 metastatic. All patients were of Caucasian background, with a median age of 56. Across 41 treatment cycles, the median treatment duration was 4 months. The overall response rate (ORR) was 20/23 (87%) and complete response (CR) rate was 9/23 (39%); patients treated with sonidegib achieved an ORR of 11/12 (92%) and CR of 4/12 (33%), and vismodegib-treated patients achieved an ORR of 9/11 (82%) and CR of 5/11 (45%). Patients who responded to HPI treatment also responded to a subsequent HPI rechallenge. Common treatment emergent adverse events (TEAEs) included muscle spasms, dysgeusia and alopecia. Dysgeusia was more frequent with vismodegib than sonidegib (<i>p</i> = 0.0001). There was no evidence to suggest a difference in other TEAEs between the two HPIs. Four treatment cycles were stopped due to grade 3 muscle spasm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In our cohort of 23 patients being treated with HPI, the ORR was 87% and CR was 39%. All patients who experienced TEAEs and had a drug holiday successfully responded to HPI rechallenge. TEAEs, particularly muscle spasms, are common reasons for treatment cessation. Clinicians should implement strategies to mitigate TEAE to improve drug survivability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e248-e254"},"PeriodicalIF":2.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyodermatitis vegetans confined to the umbilicus: Report of 2 cases","authors":"Natsuko Matsumura MD,&nbsp;Tomoko Hiraiwa MD,&nbsp;Toshiyuki Yamamoto PhD","doi":"10.1111/ajd.14376","DOIUrl":"10.1111/ajd.14376","url":null,"abstract":"<p>Pyodermatitis pyostomatitis vegetans is a rare variant of neutrophilic disorders, affecting the intertriginous areas such as axilla and groin, umbilicus, as well as the oral mucosa. We herein describe 2 female patients, in both of whom the umbilicus was restrictedly involved.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e276-e277"},"PeriodicalIF":2.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single-centre study on 485 patients","authors":"Gabriele Perego MD,&nbsp;Italo Francesco Aromolo MD,&nbsp;Francesca Barei MD,&nbsp;Martina Zussino MD,&nbsp;Luca Valtellini MD,&nbsp;Angelo Valerio Marzano MD,&nbsp;Silvia Mariel Ferrucci MD","doi":"10.1111/ajd.14372","DOIUrl":"10.1111/ajd.14372","url":null,"abstract":"&lt;p&gt;Approximately 60% of atopic dermatitis (AD) involve the hands.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; As exposed areas, the hands are susceptible to physical and chemical factors, such as low temperatures, allergens, UV rays, and irritants. These factors can damage the skin barrier, promoting the inflammatory flare-ups of AD and making this area potentially more resistant to treatment.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Hands are essential tools for daily activities, and the presence of AD in this area significantly impacts the patient's quality of life (QoL).&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signalling, is highly effective for treating AD, although its specific efficacy on the hands has been minimally assessed in the literature.&lt;span&gt;&lt;sup&gt;4-9&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;A single-centre, retrospective, study was conducted on 485 patients with severe AD involving the hands, all of whom were treated with dupilumab (loading dose of 600 mg, followed by 300 mg every 2 weeks via subcutaneous injections). Two hundred and fifty-five were male (52.5%), with a mean age of 38 years at the start of treatment (min–max, 13–88). In patients with suspected allergic contact dermatitis superimposed on AD, patch tests were performed, and if positive, the patients were excluded from the study. For clinical assessment, the Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Control Tool (ADCT) and Dermatology Life Quality Index (DLQI) were used. Data were collected at baseline, and every 4 months during treatment. Complete remission (CR) was defined as an EASI score = 0 and Pruritus NRS = 0 at the follow-up visit in a patient not using topical corticosteroids or calcineurin inhibitors in the previous 4 months. Patients enrolled in the study were allowed to use emollient creams throughout the observation period. A &lt;i&gt;t&lt;/i&gt;-test or Mann–Whitney &lt;i&gt;U&lt;/i&gt;-test was used, as appropriate, to investigate potential differences in ADCT and DLQI scores between clinical groups. All statistical analyses were two-tailed, with an alpha error = 0.05. A &lt;i&gt;p&lt;/i&gt; &lt; 0.05 was considered significant.&lt;/p&gt;&lt;p&gt;After 4 months of therapy, 62.7% of patients achieved CR in the hands. This response rate increased to 76.5% after 1 year and 85.6% after 3 years of treatment (Figure 1). In all comparisons (M4, M12 and M24), the DLQI and ADCT scores were significantly higher in non-responder patients compared to responders, except for the comparison of DLQI scores at 4 months (Table 1).&lt;/p&gt;&lt;p&gt;Phase III clinical trials have demonstrated the effectiveness of dupilumab in treating AD across different anatomical regions; however, the hands have not been specifically considered.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; The evidence is based on real-life data: Vittrup et al. observed that 65% of 104 patients with AD achieved CR after 1 year of treatment with dupilumab—a percentage similar to or even better than that observed in other areas.&lt;span&gt;&lt;sup&gt;4&lt;/su","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e263-e265"},"PeriodicalIF":2.2,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with risankizumab for nivolumab-induced psoriasis in a patient with metastatic clear cell renal carcinoma","authors":"Paulo Ricardo Criado,&nbsp;Luiza Keiko M. Oyafuso,&nbsp;Andreia Costa,&nbsp;Natasha Maia Pansani e Arantes,&nbsp;Suelen Patricia dos Santos Martins,&nbsp;Tiago Torres","doi":"10.1111/ajd.14368","DOIUrl":"10.1111/ajd.14368","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e273-e275"},"PeriodicalIF":2.2,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality-of-life evaluation in hidradenitis suppurativa in Australia: Validation and outcomes of the HiSQOL questionnaire","authors":"Kyle Wu MD,&nbsp;Conor Larney MD,&nbsp;Gill Marshman MBBS FACD,&nbsp;Lynda Spelman MBBS FACD,&nbsp;Diana Rubel MBBS FACD,&nbsp;Erin Mcmeniman MBBS PhD FACD,&nbsp;Emma Veysey MBBS FACD,&nbsp;Helen Saunders MBBS FACD,&nbsp;John W. Frew MBBS PhD FACD","doi":"10.1111/ajd.14370","DOIUrl":"10.1111/ajd.14370","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory disease with significant impact upon quality of life. Generic quality-of-life measures suffer from decreased face validity and content validity, leading to the development of disease-specific quality-of-life measures such as the Hidradenitis Suppurativa Quality of Life (HiSQOL) outcome measure. The aim of this study was to validate the use of the HiSQOL in the Australian population and evaluate the quality-of-life impact in HS patients in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 301 patients were recruited and consented to be involved in this study. All participants were invited to complete the HiSQOL questionnaire along with basic demographic and disease information, the DLQI and HADS anxiety and depression scale. Participants were then asked to repeat the questionnaires 14 days later to assess test–retest reliability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean HiSQOL score was 46.5 out of a possible total score of 76 (SD = 24.2) indicating a very large impact on quality of life. Based upon the published validity bands this corresponds to a very large impact on quality of life. Validation statistics indicated a high degree of internal consistency (Cronbach's alpha = 0.956) with expected levels of convergent validity and excellent test–retest reliability (<i>p</i> = 0.95). Multiple regression analysis indicated individuals with a younger age of onset and positive family history had significantly greater quality-of-life impact as measured by the HiSQOL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The HiSQOL is a valid, reliable measure for assessing the quality-of-life impact of HS. Significant factors influencing quality of life include age of onset and family history. Longitudinal measurements will enable evaluation of the impact of therapy upon QOL in the Australian context.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"630-635"},"PeriodicalIF":2.2,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-utility of sirolimus in the treatment of vascular malformations","authors":"Grace Xiaoying Li BSc (Med) Hons,&nbsp;Deshan Frank Sebaratnam FACD","doi":"10.1111/ajd.14369","DOIUrl":"10.1111/ajd.14369","url":null,"abstract":"<p>Sirolimus is being increasingly employed to manage specific vascular anomalies. We performed an exploratory cost-utility analysis to evaluate sirolimus as a treatment for vascular malformations from the Australian healthcare system perspective. Over a one-year time horizon, sirolimus treatment was associated with an increased expenditure of AU$2832.80 and a gain of 0.08 quality-adjusted life years (QALYs) when compared to supportive care, resulting in an incremental cost-effectiveness ratio of AU$35,410/QALY. By most metrics, sirolimus would be considered a cost-effective treatment for vascular malformations.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e259-e262"},"PeriodicalIF":2.2,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in non-invasive imaging for dermatofibrosarcoma protuberans: A review","authors":"Yanci A. Algarin BS,&nbsp;Anika Pulumati BA,&nbsp;Jiali Tan BS,&nbsp;Nathalie C. Zeitouni MD, FAAD","doi":"10.1111/ajd.14366","DOIUrl":"10.1111/ajd.14366","url":null,"abstract":"<p>Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma characterized by an asymmetric, infiltrative growth pattern and a high risk of local recurrence. This study aims to evaluate the effectiveness of various imaging modalities in the assessment and management of DFSP. Nine imaging modalities were reviewed including: Ultrasound (US), High-Frequency Doppler Ultrasound (HFUS), Computed tomography (CT), Positron emission tomography–computed tomography (PET-CT), and Magnetic Resonance Imaging (MRI), High-resolution-MRI (HR-MRI), Magnetic Resonance Spectroscopy (MRS), Optical Coherence Tomography (OCT), and Dermatoscopy. Imaging is mainly used for preoperative assessment and surgical planning, not routine diagnosis. US is effective for initial evaluations, demonstrating superior ability in detecting muscle invasion and defining tumour boundaries (sensitivity – 81.8%, specificity – 100%). MRI is valuable for preoperative evaluation, surgical planning, and monitoring DFSP recurrence. It more accurately assesses tumour depth than palpation, with a sensitivity of 67% and specificity of 100%, but was inferior when compared to US. CT is utilized in cases of suspected bone involvement or pulmonary metastasis. For advanced or recurrent DFSP, PET-CT helps manage treatment responses and imatinib therapy. Emerging technologies like MRS and OCT show potential in improving diagnostic accuracy and defining surgical margins, though more data are needed. US, MRI, and CT are the primary imaging modalities for DFSP. Emerging technologies like HR-MRI, PET-CT, MRS, and OCT hold promise for refining diagnostic and management strategies. Integrating multiple technologies could enhance management, particularly in atypical or aggressive cases. Further studies are required to refine imaging protocols and improve DFSP outcomes.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"610-620"},"PeriodicalIF":2.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyoderma gangrenosum during infliximab in severe hidradenitis suppurativa: A paradoxical event","authors":"Silvia Giordano,&nbsp;Federica Repetto,&nbsp;Sara Boskovic,&nbsp;Gabriele Roccuzzo,&nbsp;Michela Ortoncelli,&nbsp;Paolo Dapavo,&nbsp;Simone Ribero,&nbsp;Pietro Quaglino","doi":"10.1111/ajd.14367","DOIUrl":"10.1111/ajd.14367","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 8","pages":"e270-e272"},"PeriodicalIF":2.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma documented arising in an involuting naevus 3 years after cessation of monitoring","authors":"Christine Lee Bachelor Nursing, SFC (Skin Cancer Diagnostics),&nbsp;Sarah Coleman Grad Cert Nursing, SFC (Skin Cancer Diagnostics),&nbsp;Aksana Marozava MD,&nbsp;Blake O'Brien MBBS, FRCPA,&nbsp;Cliff Rosendahl MBBS, PhD","doi":"10.1111/ajd.14365","DOIUrl":"10.1111/ajd.14365","url":null,"abstract":"&lt;p&gt;A 35-year-old female, with no family history of melanoma but with a personal history of three previous melanomas, presented for a routine skin examination in 2023. She had been treated for melanoma in situ on the right forearm at age 12, with subsequent primary invasive melanomas on the scalp at ages 21 and 26. Because of her categorisation as high risk, she was having 6-monthy whole-body skin examinations as well as sequential digital dermatoscopic imaging (SDDI) of multiple randomly selected skin lesions.&lt;/p&gt;&lt;p&gt;As part of this process one pigmented skin lesion over the upper thoracic spine (Figure 1, black arrow) was monitored annually from 2017 and as it was observed to become smaller, then stable on sequential images (Figure 2, 2017–2020), monitoring was suspended in 2020.&lt;/p&gt;&lt;p&gt;In 2023 at routine examination by the treating clinician, assisted by a qualified nurse-diagnostician, with active reference to total body photography (TBP) images, an observation was made by the nurse that the lesion previously monitored (Figure 1, black arrow) was now a similar size to a previously larger lesion below it (Figure 1, white arrow). A dermatoscopic image was taken and when compared with the previous image from 2020, significant progressive change in all quadrants was identified (Figure 2, 2023). The lesion was excised and submitted for histology, accompanied by relevant clinical information and dermatoscopic images. Histological examination was consistent with early melanoma in situ, with regression, arising in a pre-existing compound naevus (Figure S1). The subject patient has provided informed consent to the publication of their information contained within this manuscript.&lt;/p&gt;&lt;p&gt;Sequential digital dermatoscopic imaging of randomly selected multiple naevi has been shown to have diagnostic efficacy for patients at high risk of melanoma.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; As well as facilitating diagnosis of early, and even featureless melanomas,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; it has been demonstrated to improve specificity, avoiding excision of biologically indolent lesions.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; It has been shown that monitoring may need to be continued long-term to detect slow-growing melanomas, in one large study major changes only being evident after a mean follow-up of 33 months.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The use of TBP and SDDI, known as the ‘two-step method of digital follow-up’ has been suggested as an ideal surveillance strategy for high-risk melanoma patients.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; It is also known that the provision of relevant clinical information has been shown to improve pathologists' confidence in, and accuracy of histological diagnosis.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;A meta-analysis of naevus-associated melanomas in 2017 reported that most cutaneous melanomas arose de novo, 29.1% arising in association with a naevus. In contrast to a commonly held misconception, melanoma-associated naevi were most frequently non-dysplastic, the bland dermal nae","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e221-e223"},"PeriodicalIF":2.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142256665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}